|
| 37871306 | Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. | Blood Adv | 2024 |
| 36706345 | Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study. | JCO Clin Cancer Inform | 2023 |
| 37597685 | Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation. | Transplant Cell Ther | 2023 |
| 37339484 | Genomic landscape of TP53-mutated myeloid malignancies. | Blood Adv | 2023 |
| 37327120 | Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor. | Blood Adv | 2023 |
| 37128256 | SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. | EClinicalMedicine | 2023 |
| 36711871 | Genomic landscape of <i>TP53</i> -mutated myeloid malignancies. | medRxiv | 2023 |
| 34797911 | Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. | Blood | 2022 |
| 35709710 | Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. | Blood Cancer Discov | 2022 |
| 35545171 | NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. | J Natl Compr Canc Netw | 2022 |
| 35598841 | Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. | Transplant Cell Ther | 2022 |
| 35907408 | Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. | Lancet Haematol | 2022 |
| 35895896 | Proteomic and phosphoproteomic landscapes of acute myeloid leukemia. | Blood | 2022 |
| 35877996 | The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. | Blood | 2022 |
| 35130502 | NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. | J Natl Compr Canc Netw | 2022 |
| 34873300 | Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. | Leukemia | 2022 |
| 35236053 | Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. | Haematologica | 2022 |
| 35196021 | Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. | Sci Transl Med | 2022 |
| 35019859 | Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia. | Blood Cancer Discov | 2022 |
| 33467957 | A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. | Leuk Lymphoma | 2021 |
| 33704937 | Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. | N Engl J Med | 2021 |
| 34845035 | Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. | Proc Natl Acad Sci U S A | 2021 |
| 34619434 | Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. | Leuk Res | 2021 |
| 34106753 | Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. | J Clin Oncol | 2021 |
| 34036230 | Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. | JCO Precis Oncol | 2021 |
| 31563575 | The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. | Biol Blood Marrow Transplant | 2020 |
| 31910384 | NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. | J Natl Compr Canc Netw | 2020 |
| 31755139 | Ruxolitinib for steroid-refractory acute graft-versus-host disease. | Transpl Int | 2020 |
| 31753931 | Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. | Haematologica | 2020 |
| 31881282 | Role of Transplant Conditioning Regimen Intensity in High-Risk Acute Myelogenous Leukemia. | Biol Blood Marrow Transplant | 2020 |
| 32976742 | IFNL4 and donor selection for matched unrelated donor haematopoietic stem-cell transplantation. | Lancet Haematol | 2020 |
| 32826231 | Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. | Cancer Discov | 2020 |
| 32871558 | Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. | J Natl Compr Canc Netw | 2020 |
| 32468720 | The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study. | Transpl Int | 2020 |
| 30467844 | Exome analysis of treatment-related AML after APL suggests secondary evolution. | Br J Haematol | 2019 |
| 31801591 | Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome. | J Immunother Cancer | 2019 |
| 31358485 | A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2019 |
| 31306039 | Factors Associated With Clinical Deterioration Among Patients Hospitalized on the Wards at a Tertiary Cancer Hospital. | J Oncol Pract | 2019 |
| 30923101 | Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia. | Haematologica | 2019 |
| 30307478 | Bone Marrow Biopsy Needle Type Affects Core Biopsy Specimen Length and Quality and Aspirate Hemodilution. | Am J Clin Pathol | 2019 |
| 28744009 | Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. | Leukemia | 2018 |
| 29803753 | Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. | Biol Blood Marrow Transplant | 2018 |
| 30207916 | Mutation Clearance after Transplantation for Myelodysplastic Syndrome. | N Engl J Med | 2018 |
| 30114560 | Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. | Leuk Res | 2018 |
| 30006305 | Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. | Biol Blood Marrow Transplant | 2018 |
| 30563883 | HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. | Blood Adv | 2018 |
| 30380364 | Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. | N Engl J Med | 2018 |
| 29386642 | Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. | Nat Commun | 2018 |
| 29463563 | First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. | Blood | 2018 |
| 29567774 | Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. | Haematologica | 2018 |